Recently added articles from Worldwide Biotech:
HEALTHLINX CONFIRMS COLLABORATORS FOR OVPLEX OVARIAN CANCER STUDY.(Clinical report)
Dec 01, 2009 ... Melbourne: HealthLinx Limited (ASX:HTX) has confirmed its collaborators who will work with the company on its second larger OvPlex(tm) ovarian cancer diagnostic trial. The trial using 1150 samples will take place in Australia, Singapore and the UK and include: * Professor Lewis ...
COMPUGEN PRESENTS DAC BLOCKERS PLATFORM/INITIAL PRODUCT CANDIDATES.
Dec 01, 2009 ... Speaking in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. (NASDAQ: CGEN) project manager Dr. Yossef Kliger provided an overview of Compugen's DAC Blockers Platform and reviewed disease model data for selected product candidates. Among the product candidates reviewed ...
CUMBERLAND/PHEBRA PTY LTD. TO COMMERCIALIZE CALDOLOR.
Dec 01, 2009 ... Nashville, Tenn., (October 29, 2009) - Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX) and Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, today announced they have entered into an exclusive partnership for the commercialization of Caldolor(r) (ibuprofen) Injection in ...
ACM GLOBAL CENTRAL LAB CELEBRATES 10 YRS OF PROVIDING SERVIVES.
Dec 01, 2009 ... ACM Global Central Laboratory, the global central lab that continually defines the customer-service standard with its flexible approach, The European arm of ACM Global Central Laboratory, based in York, England, initiated as Pivotal Laboratories Limited in 1999 and since then ...
QRXPHARMA/LIAONING NUOKANG MEDICINES TO DEVELOP VENOMICS.
Nov 01, 2009 ... QRxPharma(OTCQX:QRXPY), has announced a strategic alliance with Liaoning Nuokang Medicines Co. Ltd. (Nuokang), a Chinese biopharmaceutical company based in Shenyang, China, to develop and commercialise QRxPharma's venomics assets for the Chinese market. The strategic alliance involves ...